University Hospital Tuebingen: clinical-trial pipeline
University Hospital Tuebingen is the sponsor of 488 clinical trials in ClinicalTrials.gov and the EU CTIS portal; 91 are not yet finished and 2 were first posted in the last 90 days. Source: Arcadium Data, data as of .
Trials by phase
| Phase | Trials |
|---|---|
| Not applicable | 356 |
| Phase 2 | 48 |
| Phase 1 | 23 |
| Phase 3 | 20 |
| Phase 1/2 | 17 |
| Phase 4 | 14 |
| Phase 2/3 | 10 |
Trials by status
| Status | Trials |
|---|---|
| Completed | 241 |
| Unknown | 117 |
| Recruiting | 70 |
| Terminated | 23 |
| Withdrawn or not authorised | 15 |
| Not yet recruiting | 12 |
| Active, not recruiting | 9 |
| Suspended or halted | 1 |
Condition areas
| Area | Trials |
|---|---|
| Oncology | 112 |
| Metabolic and endocrine (diabetes, obesity) | 59 |
| Rare and genetic diseases | 49 |
| Cardiovascular | 41 |
| Neurology | 39 |
| Infectious disease and vaccines | 37 |
| Psychiatry and mental health | 32 |
| Women's health and obstetrics | 23 |
| Gastroenterology and liver | 22 |
| Respiratory | 19 |
| Nephrology and urology | 18 |
| Haematology | 13 |
Countries
| Country | Trials |
|---|---|
| Germany | 442 |
| Spain | 8 |
| Austria | 5 |
| Switzerland | 5 |
| Italy | 5 |
| United Kingdom | 4 |
| France | 3 |
| Poland | 3 |
| Sweden | 3 |
| Belgium | 2 |
| Finland | 2 |
| Luxembourg | 2 |
| Netherlands | 2 |
| Benin | 1 |
| China | 1 |
Latest changes
| Day | Change | Trial |
|---|---|---|
| 2026-10-21 | New trial posted | Long-Term Cognitive Recovery After Arteria Cerebri Media Ischemia: A Digital Assessment U… |
| 2026-10-06 | New trial posted | Multi-peptide Vaccination and Bispecific PSMAxCD3 Antibody Treatment in Patients With Pro… |
Open trials
The 25 most recently changed open trials.
| Registry id | Title | Phase | Status | Countries |
|---|---|---|---|---|
| NCT05389319 | A Study to Assess the Safety and Immunogenicity of a COVID-19 Vaccine Booster in Healthy Adults | Phase 1 | Active, not recruiting | Germany |
| NCT06290557 | First-in-man Single-dose and Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy ofHY-133 | Phase 1 | Recruiting | Germany |
| NCT04104607 | The Bispecific PSMAxCD3 Antibody CC-1 in Patients with Castration Resistant Prostate Carcinoma | Phase 1 | Recruiting | Germany |
| NCT05112549 | Intrathecal Application of PD1 Antibody in Metastatic Solid Tumors With Leptomeningeal Disease (IT-PD1/ NOA 2… | Phase 1 | Recruiting | Germany |
| NCT05871021 | Protective VEGF Inhibition for Isotoxic Dose Escalation in Glioblastoma | Phase 2 | Active, not recruiting | Germany |
| NCT05366218 | Tafasitamab (MOR00208) in Pediatric Patients With Relapsed or Refractory Acute B Lineage Leukemia | Phase 1/2 | Recruiting | Germany |
| NCT06094101 | Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision) | Phase 1/2 | Recruiting | Germany |
| NCT07108868 | A Phase I Dose Finding Study of MB-CART2219.1 | Phase 1 | Recruiting | Germany |
| NCT06789198 | Peptide Vaccine for Fibrolamellar Hepatocellular Carcinoma Patients and Other Tumor Entities Carrying the Dri… | Phase 1 | Recruiting | Germany |
| NCT07151378 | Intestinal Levodopa + Entacapone Therapy (Lecigon®) to Counteract Dopaminergic Desensitization and Neuropsych… | Phase 3 | Recruiting | Germany |
| NCT07214064 | Venetoclax- Augmented Treosulfan-Based Reduced Intensity Conditioning Before Allogeneic Stem Cell Transplanta… | Phase 2 | Recruiting | Germany |
| NCT07055087 | Prevent Cognitive Decline in GBA-associated Parkinson's Disease | Phase 2 | Recruiting | Germany, Spain, France, United Kingdom +3 |
| NCT07860047 | Multi-peptide Vaccination and Bispecific PSMAxCD3 Antibody Treatment in Patients With Prostate Cancer | Phase 2 | Not yet recruiting | Germany |
| NCT07179029 | Anesthesia Induced Myocardial Injury in Non-cardiac Surgery (AIMY) | Not applicable | Recruiting | Germany |
| NCT05914974 | Immunotherapy-related CRP Kinetics in Metastatic Gynecological Malignancies | Not applicable | Recruiting | Germany |
| NCT04270578 | Gestational Diabetes | Not applicable | Recruiting | Germany |
| NCT07132333 | Molecular Inflammation Board at the Center for Personalized Medicine | Not applicable | Recruiting | Germany |
| NCT06345664 | Interdisciplinary E-health Based Follow-up of Preterm Born Children | Not applicable | Active, not recruiting | Germany |
| NCT06060184 | Initiative for Clinical Long-read Sequencing | Not applicable | Not yet recruiting | Germany |
| NCT03503149 | Molecular Tumor Board at the Center for Personalized Medicine Tübingen | Not applicable | Recruiting | Germany |
| NCT02338167 | Praegnant Breast Cancer: Early/Advanced/Metastatic | Not applicable | Recruiting | Germany |
| NCT04057690 | Automatic PredICtion of Edema After Stroke | Not applicable | Active, not recruiting | Austria, Germany, United Kingdom |
| NCT04878666 | Prospective Assessment of Quality of Life in Patients With Locally Recurrent Breast Cancer and Hyperthermic R… | Not applicable | Recruiting | Germany |
| NCT06431087 | Effect of a Mindfulnes Program "Healthy Under Stress" on Stress: A Prospective Intervention Study | Not applicable | Recruiting | Germany |
| NCT06130371 | Stress, Inflammation and Neuroimaging in Major Depressive Disorder as Compared to Premenstrual Dysphoric Diso… | Not applicable | Recruiting | Germany |
All sponsors: clinical-trial pipeline by sponsor.
Track a sponsor's pipeline
The API returns the same trials by sponsor website, phase, status, condition and country with a change feed, joined to hiring and public contract awards. Try it without a key on one sponsor.
Sources: ClinicalTrials.gov (U.S. National Library of Medicine, public domain) and the EU Clinical Trials Information System public portal (European Medicines Agency), data as of 2026-10-25. A trial that one register cites in the other is shown once. Organisation-level data only: investigators, contact persons and site names are not stored, and a sponsor that could be a private person is withheld. Sponsor-to-website matches are made by name and can be wrong; check the register before relying on a record. Independent of the NLM, NIH and EMA.
Cite as: Arcadium Data, "University Hospital Tuebingen clinical trials: 91 open, 30 in phase 3", https://arcadiumdata.io/clinical-trials/sponsor/university-hospital-tuebingen/, data as of 2026-10-25.